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Background: Erythropoietin (EPO) is known to improve exercise performance by increasing oxygen blood transport
and thus inducing a higher maximum oxygen uptake (VO2max). Furthermore, treatment with (or overexpression of)
EPO induces protective effects in several tissues, including the myocardium. However, it is not known whether EPO
exerts this protective effect when present at physiological levels. Given that EPO receptors have been identified in
skeletal muscle, we hypothesized that EPO may have a direct, protective effect on this tissue. Thus, the objectives of
the present study were to confirm a decrease in exercise performance and highlight muscle transcriptome
alterations in a murine EPO functional knock-out model (the EPO-d mouse).
Methods: We determined VO2max peak velocity and critical speed in exhaustive runs in 17 mice (9 EPO-d animals
and 8 inbred controls), using treadmill enclosed in a metabolic chamber. Mice were sacrificed 24h after a last
exhaustive treadmill exercise at critical speed. The tibialis anterior and soleus muscles were removed and total RNA
was extracted for microarray gene expression analysis.
Results: The EPO-d mice’s hematocrit was about 50% lower than that of controls (p < 0.05) and their performance
level was about 25% lower (p < 0.001). A total of 1583 genes exhibited significant changes in their expression levels.
However, 68 genes were strongly up-regulated (normalized ratio > 1.4) and 115 were strongly down-regulated
(normalized ratio < 0.80). The transcriptome data mining analysis showed that the exercise in the EPO-d mice
induced muscle hypoxia, oxidative stress and proteolysis associated with energy pathway disruptions in glycolysis
and mitochondrial oxidative phosphorylation.
Conclusions: Our results showed that the lack of functional EPO induced a decrease in the aerobic exercise
capacity. This decrease was correlated with the hematocrit and reflecting poor oxygen supply to the muscles. The
observed alterations in the muscle transcriptome suggest that physiological concentrations of EPO exert both direct
and indirect muscle-protecting effects during exercise. However, the signaling pathway involved in these protective
effects remains to be described in detail.
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The hematopoietic effect of erythropoietin (EPO) is
known to increase exercise performance by inducing a
higher maximal oxygen uptake (VO2max) in athletes.
This EPO cytokine is also used as a therapeutic in
patients. Indeed, disease-associated, low levels of EPO
lead to a drop in hematocrit (Htc), marked anemia and
decreased exercise performance. Congestive heart fail-
ure (CHF) and chronic kidney failure (CKF) lead to
progressive renal dysfunction and a decrease in EPO
levels, with reduced erythrocyte production by bone
marrow. Thus, reduced exercise capacity is a clinical
hallmark in CHF and CKF patients, who typically show
lower VO2max values than age-matched normal sub-
jects. Indeed, as kidney function declines over time,
there is a corresponding decline in exercise perform-
ance [1,2]. The normalization of hemoglobin concen-
tration in these patients by administration of EPO-
stimulating agents improves exercise capacity and raises
VO2max by increasing oxygen supply to muscles. Fur-
thermore, the higher the increase in hemoglobin levels,
the greater the improvement in exercise duration [3-6].
This effect continues at above-physiological levels of
EPO. In cycling and running, the illegal administration
of exogenous EPO is used to artificially increase per-
formance levels (despite the occurrence of adverse
effects). In addition, administration of recombinant
human EPO (rHuEpo) was found to increase time to
swimming exhaustion in a murine CKF model [7-9].
However, it is not known whether EPO directly affects
muscle functions.
Furthermore, it is now well accepted that EPO’s bio-
logical activity is not restricted to regulation of erythro-
poiesis. In fact, EPO is a member of the cytokine
superfamily and has significant homology with mediators
of growth and inflammation. The EPO receptor (EPO-R)
is also known to be present in heart, neuronal, retinal,
renal and muscle tissues [10-13]. Unsurprisingly, add-
itional biological functions for EPO have been identified.
The synthetic form of EPO has been shown to exert re-
markable, tissue-protective effects on several tissues.
The broad efficiency of EPO depends on its key role in
various protective pathways, such as inhibition of apop-
tosis, vascular restoration, attenuation of inflammatory
responses and better overall function [10,14-18]. How-
ever, EPO’s protective role in muscle tissue has been
mainly studied on cardiac muscle and in vivo and in
various animal models [19]. It has been shown that (i)
rHuEpo pre-treatment attenuates myocardial infarct size
and (ii) EPO has a cardioprotective effect on ischemia-
reperfusion injury in various species [20-25]. This effect
was hematocrit-independent (i.e. directly related to
EPO), since EPO improved cardiac function at a dose
that did not increase the hematocrit [26].However, it is not known whether physiological levels
of EPO exert a protective role in skeletal muscles. In
view of (i) the identification of EPO-R in muscle tissue
and (ii) the known tissue-protective effects of EPO, we
hypothesized that physiological levels of the cytokine
may have protective effects on muscle.
Thus, we used a murine EPO functional knock-out
model (the EPO-d mouse, based on EPO immunization)
to decrease active circulating levels of EPO and thus in-
vestigate the loss of function's impact on exercise per-
formance and on the muscle transcriptome. The EPO-d
mice had a low Htc and so we expected them to have
lower performance levels and more impaired muscle oxi-
dative function than inbred, control mice. Hence, the
objectives of the present study were to confirm a de-
crease in exercise performance and highlight muscle
transcriptome alterations in a murine EPO functional
knock-out model (the EPO-d mouse).
Methods
Ethical approval
All protocols were approved by our institution’s Animal
Care and Use Committee and complied with the Council
of Europe’s European Convention for the Protection of
Vertebrate Animals Used for Experimental and Other
Scientific Purposes.
The protein functional knock-out was obtained by
immunoneutralization of circulating EPO, according to
the vaccination method developed by NokadW [27].
Briefly, when immunization is performed with a modi-
fied self-protein like EPO, cross-reactive neutralizing
antibodies are secreted and deplete the circulating pro-
tein. Repeated injections of the modified protein modu-
late the immune response and, in the present case,
enabled us to study the effects of the loss of active, cir-
culating EPO and the subsequent drop in Htc (US pa-
tent 2008/0220015A1). We always checked each EPO-d
mouse’s Htc (down to as low as 20%) before initiating
the exercise tests.
A total of 17 adult female C57Bl6/J mice (9 EPO-d
mice and 8 control inbred animals) were included in this
study. They were ear–punched for identification. Male
were excluded to avoid a potential gender effect.
The mice were five months old when they performed
the exercise tests. The animals were kept in an animal
facility (CERFE, Genopole, Evry, France) in a specific
and opportunist pathogen-free environment and at a
temperature of 22°C with 12h:12h light-dark cycles. The
animals were supplied with water and food ad libitum.
Exercise protocols
Devices
The exercise testing protocol was performed on a
single-lane motorized treadmill (Columbus Instruments,
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m.min-1). The rear of the treadmill was equipped with a
low-voltage, electric stimulating bar, to encourage each
mouse to run. The bar was set to deliver 0.2 mA at a fre-
quency of 0.25 Hz, which caused an uncomfortable shock
but did not injure the animal.
Measurements and data recording
Oxygen consumption (VO2) was measured by means of
a rapid-flow, open-circuit, indirect calorimeter. The
single-lane test treadmill was placed in a metabolic
chamber. Ambient air was fed through the chamber at a
rate of 0.66 l.min-1; the flow was chosen such that the
O2 difference across the chamber was within the sensor’s
range (-0.3 to -0.8% O2). A fan mixed the incoming air
with the air around the treadmill and blew it towards
the animal. The air flowed from the front of the tread-
mill to the rear and then returned under the belt to-
wards the front. This created a rapid, circular "loop" of
mixed gases (incoming "fresh" air and accumulated
exhaled gases) from which a sample was drawn for ana-
lysis (the Oxymax from Columbus Instruments). Gas
samples were taken every 5s and dried prior to measure-
ment of the oxygen and carbon dioxide fractions.
The gas analyzers were calibrated with standardized
gas mixtures (Air Products, Paris, France) before every
test session, as recommended by the manufacturer. The
treadmill test provided an estimate of VO2max, defined
as the highest oxygen consumption attained over a 15-
second period during the testing protocol. To allow
rapid comparison over a wide range of body weights
(and especially with human data), dimensional analysis
and empirical studies show that VO2 should be
expressed in relation to body mass raised to the power
of 0.75. [28,29].
Familiarization
The mice were familiarized with the treadmill over a one-
week period via the completion of four 10-min running
sessions from 0 to 9 m.min-1 (0, 3, 6 and 9 m.min-1). All
mice succeeded in running for the required time at an in-
tensity of 9 m.min-1. The velocity was not increased
above this value, in order to avoid a training effect. The
mice subsequently performed an incremental exercise
test.
Incremental test load: Peak velocity, blood lactate and
_VO2max determination
Starting from a speed of 10 m.min-1, the exercise inten-
sity was increased by 3 m.min-1 every 3 min, with an in-
cline of 0%. Exercise continued until exhaustion, which
was defined as an inability to maintain the running
speed despite contact with the electric grid for more
than 5 sec. All measurements were made by the sameinvestigator. The last stage completed by the mouse was
defined as the peak velocity (vPeak). Blood lactate levels
were measured before the exercise and two minutes
after the end of the exercise ([La]INC). After local anti-
sepsis with alcohol, the distal 2mm of the animal’s tail
was cut off. To avoid contamination, the first drop of
blood was discarded. Next, a 5 μl blood sample was col-
lected on a small test strip and the blood lactate concen-
tration was measured with a Lactate Pro assay (Arkray
Inc., Kyoto, Japan).
Steady-state intensity exercise: The critical speed
determination
The protocol consisted of four constant-speed runs (18–
51 m/min) leading to exhaustion within one hour, as
described in an earlier study [30]. A single trial was per-
formed per day, and the protocol covered a period of 4
days. The time to exhaustion was recorded at each
speed. Two parameters were used to estimate endurance
performance: the distance the mice were able to cover at
a given speed (limit distance, in meters) and the time
needed to cover the distance (limit time, seconds). The
critical speed (CS) was calculated, from the slope (a) of
the regression line, plotting the distance (y) vs. the time
to exhaustion (x) from the four tests, according to the
equation y= ax+ b.
Exhaustive exercise at the critical speed and muscle
collection
At least two days after the end of the determination of
CS, vPeak and VO2max, all animals ran at their individual
CS until exhaustion. We recorded the time to exhaus-
tion and the blood lactate concentrations before and 2
min after the end of exercise ([La]SS). Mice were sacri-
ficed by cervical dislocation 24h later. The tibialis anter-
ior and soleus muscles were rapidly removed, immerged
for 2 hours in RNAlater reagent (Ambion, Austin, TX)
and then frozen in liquid nitrogen. The samples were
then stored at -80°C prior to RNA extraction for micro-
array and RT-qPCR analysis.
Muscle gene expression analysis
Production of the murine long oligonucleotide microarray
Gene expression analysis was performed using a 25K
mouse long oligonucleotide microarray [Gene Expres-
sion Omnibus accession number GPL8349: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL8349, [31]].
The microarrays were spotted (LEFG, CEA, Evry,
France) by printing the probes (suspended in a spotting
buffer composed of 1:1 v/v dimethyl sulfoxide (DMSO)
and Tris EDTA buffer) on hydrogel slides (Nexterion,
Schott) with a Microgrid-II robot (Genomic Solutions
Inc., Ann Arbor, MI).
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Total RNA was extracted from each muscle sample
using a phenol-chloroform method (TRIZOLW reagent,
Invitrogen Life Technologies, Carlsbad, CA, USA). The
quality of total RNA was verified by micro channel elec-
trophoresis (RNA 6000 Nano LabChip, BioanalyzerW,
Agilent, Agilent technologies, Santa Clara, USA). The
total RNA concentration and purity were measured by
optical density with a spectrophotometer according to
the absorbance at 260 nm and the 260nm/280nm ab-
sorbance ratio, respectively (NanodropW, Thermo Scien-
tific, Wilmington, DE, USA). RNA was considered as
pure when the 260nm/280nm absorbance ratio was close
to 2. The total RNA extracts were stored at -80°C prior
to microarray analysis.
Microarray hybridization and signal quantification
Microarray hybridization
The tibialis anterior RNA extracts from each mouse
were pooled into the corresponding EPO-d and control
groups. Likewise, soleus muscle RNA extracts were
pooled into an EPO-d group and a control group. Eight
mouse 25K microarrays were used to analyze the sam-
ples using a dye-swap design.(2 groups x 2 muscles x 2).
Briefly, the hybridization protocol [32] included the fol-
lowing steps: after purification of the amino-modified
RNA, monofunctional forms of cyanine-3 (Cy3) or
cyanine-5 (Cy5) fluorochrome were coupled to 5 μg each
of the test and control samples using an indirect
method: the fluorochromes’ ester groups were bound to
aminoallyl groups incorporated into the RNA during
in vitro transcription. The synthesis of RNA with a
polyA tail was performed using in vitro transcription
with aminoallyl UTP. A total RNA (1 μg) was used to
start the synthesis using the in vitro transcription kit
according to the manufacturer’s protocol (Aminoallyl
MessageAmp W II aRNA, Invitrogen Life Technologies,
Carlsbad, CA, USA). This method equally increased the
number of mRNA copies of each transcript without
changing the proportion of the initial population of tran-
scripts. The purity and concentration of aminoallyl RNA
(aaRNA) were again checked by microchannel electro-
phoresis (with a RNA 6000 Nano LabChip in a Bioanaly-
zer) and spectrophotometry (Nanodrop). The aaRNAs
were stored at -80°C. The marked targets were then
mixed and hybridized on the same chip for immediate
comparison of the two nucleic acid populations. For
each sample, a dye-swap (duplicate measurement) was
performed to avoid asymmetry of marker affinity (Cy3
and Cy5). The fluorescence intensities of Cy3 (532 nm)
and Cy5 (635 nm) were imaged separately with a laser
scanner (GenePix 4000B, Molecular Device, Sunnyvale,
CA, USA). The resulting tiff images (10 μm/pixel) were
analyzed using dedicated microarray image analysissoftware (GenePix Pro 6.0 software, Molecular Device,
Sunnyvale, CA, USA) that located each spot automatic-
ally (with manual control) and quantified its fluores-
cence intensity. For each microarray, the data output
were the fluorescence intensities of all the spots corre-
sponding to each gene. These data were imported into
genomic data analysis software (Gene Spring software,
Agilent Technologies, Santa Clara, CA, USA) to
normalize the data before filtering and statistical ana-
lysis. For each sample, a duplicate analysis (dye-swap)
was made and the average fluorescence results were
used. Next, all the results were normalized per spot and
per microarray with a locally weighted scatterplot
smoothing regression method, in order to remove sys-
tematic variations. Lastly, the expression ratio was
obtained for each muscle and each gene.
Ratio = fluorescence in EPO-d muscle / fluorescence in
the corresponding control muscle
For statistical analysis, a log transformation ratio was
used to normalize the distribution. A list of the signifi-
cant genes were obtained by filtering the genes with a
cut-off T-test (p-value < 0.05). Benjamini and Hochberg
multiple testing correction was used to avoid a biased
discovery rate [33] The Student t-test detected the mean
expression ratio of replicates that differed significantly
from one (i.e. an expression ratio of 1 means that there
was no change in gene expression).
Real-time, quantitative PCR (RT-qPCR)
In order to validate the most significant results from the
microarray analysis, quantitative RT-qPCRs were con-
ducted in triplicate for the top ten up- and down-
regulated gene transcripts in muscles from both EPO -d
and control inbred mice. The primers were designed
using Primer express software (Applied Biosystems, Life
Technologies, Carlsbad, CA, USA) (Table 1). All reac-
tions were carried out in a 7500 Real-Time PCR System
(Applied Biosystems). Briefly, reverse transcription was
performed on 20 ng of the aaRNA used for microarray
hybridization. Random primers (100 ng) and 10 pmol of
dATP, dCTP, dGTP and dTTP were added to RNA in a
13 μL final volume. The reaction tubes were incubated
at 70°C for 5 min. The mixture was incubated with ran-
dom annealing primer at room temperature (~25°C) for
10 min. Four microliters of 5x first-strand buffer, 200
pmol of DTT and 200U of Superscript II reverse tran-
scriptase were added to the tube to give a 20μL final vol-
ume and incubated at 42°C for 1 hour. The enzyme was
inactivated by incubating the mixture at 70°C for 15
min. The cDNA concentration was measured in terms
of the optical density at 260 and 280 nm (Nanodrop W).
The cDNA solution was diluted in water to obtain a
final concentration of 20 ng/μL and stored at -20°C.
Complementary DNA (100 ng) obtained from aaRNA
Table 1 List of the primers used for RT-qPCR
Genes Primers Sequences 5' - > 3' Length Tm %GC
Mcptl Fwd TTCTGGACGCGGAAATGC 18 59 56
Rev CTGTTAATCCAGGGCACATGTG 22 59 50
Runx1 Fwd GCCATTTTGGGTCTGCTTTC 20 58 50
Rev TTGTCTGCGCAGGACGTTT 19 59 53
Plcb2 Fwd ACCGCATTGATGTGGTGGTA 20 58 50
Rev TGCGTACACTGCGCTCTGA 19 59 58
Ccdc130 Fwd GGTGAAAGGAAAGGCCAGAAC 21 59 52
Rev ATCGGTTGAGAGAGCCATGCT 21 60 52
Chfr Fwd AAGGAAGCCATGCCATATGC 20 59 50
Rev GGATCCTGCTCCCGTTCA 18 58 61
Ints1 Fwd GGACTGCCTGCGATCCTTTA 20 59 55
Rev GCCCACGTACTTGTGGATGA 20 58 55
Pip4k2b Fwd CCGATTCTCAGCGTCCTGAT 20 59 55
Rev CATCCGGCATTAGCATGACA 20 59 50
Isg20l2 Fwd CCAGGGAGACACATGCAGTAGAC 23 60 57
Rev CCTCTCCCCAGTGATTCTAGCTT 23 59 52
Ckm Fwd GCTGACCCCTGACCTCTACAATA 23 58 52
Rev CACCCCAGTCTGGATGACATC 21 59 57
Eno3 Fwd GCAATTGCCTGCTCCTGAAG 20 60 55
Rev GTGCAAGTTTACAGGCCTGGAT 22 59 50
Serpinb2 Fwd CAGGCACAAGCAGGAGATAAAA 22 58 45
Rev CCCCTGTGGTGTGTTGATTG 20 58 55
Hspb7 Fwd AGCTGATGGCACAGTCATGAAC 22 59 50
Rev GCCGAGGTCACCGATGTT 18 58 61
Chac1 Fwd GGTCATTGCCACACAGATCCT 21 58 52
Rev CTGCCAAACGCAATAAGTACTCA 23 58 43
Nrap Fwd GCTTTCTGTTAATAACTTCGTGAGTCA 27 58 37
Rev GACGCTAGTGAACGTGTTGTTCTT 24 59 46
Zp2 Fwd TGACTGCTGGGCAACTTCTTC 21 59 52
Rev TCACAGCCATCCATGACAATCT 22 59 45
Atp1a2 Fwd CATAAGGCTCAGGAGTCACAGAAG 24 58 50
Rev CACAGGGAGAAGTGGCAGCTA 21 59 57
Ctsd Fwd GGCGTCTTGCTGCTCATTCT 20 59 55
Rev ACTTGCGCAGAGGGATTCTG 20 59 55
Socs3 Fwd GCCACCTGGACTCCTATGAGAA 22 59 55
Rev GGAGCATCATACTGATCCAGGAA 23 59 48
Cish2 (endogenous Fwd TCCAGATGTGCAAGGATAAACG 22 59 45
gene) Rev GGTTTGGTCAGGTACAGGTGAAC 23 58 52
Erk1 Fwd CCTGCTGGACCGGATGTTA 19 58 58
Rev TGAGCCAGCGCTTCCTCTA 19 58 58
Epor Fwd TTGGTGTGTTTCTGGGAGGAA 21 59 48
Rev ACCCTCGAGCTGGTATGAGAAG 22 58 55
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Table 1 List of the primers used for RT-qPCR (Continued)
Hif1a Fwd TGCATCTCCATCTTCTACCCAAGT 24 60 46
Rev CCGACTGTGAGTGCCACTGTAT 22 59 55
Vegf Fwd GCAGGCTGCTGTAACGATGA 20 59 55
Rev CATGATCTGCATGGTGATGTTG 22 58 45
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each specific primer and 10μL SYBRW Green PCR Mas-
ter Mix (Qiagen, Hilden, Germany). Amplification steps
were as follows: denaturation for 10 min at 95°C, 40
cycles of denaturation at 95°C for 15 s and annealing ex-
tension at 60°C for 1 min. The comparative threshold
cycle (Ct) method was used to calculate the amplifica-
tion, as specified by the manufacturer. The expression
results of the RT-qPCR for muscles from EPO-d and
control inbred mice were normalized against the mean
Ct for the endogenous gene Cish2 (measured in all
muscle samples and found to independent of the EPO
deficiency). Each gene’s relative expression ratio in the
EPO-d mice was calculated according to the expression
of the corresponding gene in the control mice.Data mining
A biological interpretation of the data was performed
using two data-mining programs to identify the main
biological functions and the main metabolic pathway
disorders revealed by the expression profile in EPO-d
muscles. IngenuityW Pathway Analysis (www.ingenuity.
com) was used to identified the biological functions that
were the most significantly associated with the gene list
results. Significant genes whose functions had been
described in published papers were considered for the
analysis. Fischer’s exact test was used to calculate a p-
value for the probability with which each biological func-
tion assigned to a data set was due to chance alone.Table 2 Physiologic variables and metabolic indexes
during exercise in control and EPO-deficient mice
Control (n = 8) EPO-d (n= 9) p-value
Age (weeks) 21.3±3.7 19.3±1.0 NS
Weight (g) 22.7±0.9 21.7±1.28 NS
Htc (%) 40.8±2.7 19.6±2.7 0.001
vPeak (m/min) 19.0±3.2 13.9±2.3 0.004
CS (m.min-1) 16.4±2.9 11.15±1.5 0.002
VO2max (ml.kg
-0.75.min-1) 48.3±1.4 34.4±5.4 0.0005
[La]INC (mmol.l
-1) 3.3±1.1 9.4±2.6 0.007
Tlim (min) 43.2±13.3 50.3±20.8 NS
[La]SS (mmol.l
-1) 2.8±2.0 3.4±2.7 NS
Data are quoted as the mean ± SD; NS: not significant at p < 0.05; _VO2: oxygen
consumption; _VO2max :maximum _VO2.The analysis of the main metabolic pathways and their
potential dysfunctions was performed using Predict-
searchW software written in Java/Perl (Prediguard, http://
prediguard.com/predictsearch.htm), which has been pre-
viously described in [34]. This software characterizes the
pathways and functional networks in which the selected
genes are involved. Briefly, gene aliases corresponding to
the significant modulated genes were submitted as quer-
ies to PubMed in order to collect titles and abstracts of
all related publications. The results are presented in a
graph that shows the relationships between each gene
and each cell type, cellular compartment and biological
function.
Statistics
A Mann-Whitney U test was applied to compare vari-
ables in EPO-d mice with those in control mice vari-
ables. A Spearman test was used to test correlations
between exercise parameters. A three-way analysis of
variance was used to test the effects of EPO deficiency,
muscle and gene on the RT-qPCR Ct values.
Results
Exercise physiology
The two groups of mice did not differ significantly in
terms of age and weight at baseline. The EPO-d group
showed a two-fold decrease in Htc, relative to the con-
trol group (19.56 ± 2.74% and 40.75 ± 2.71%, respectively;
p < 0.0001). The VO2max, vPeak, and CS performance in-
dexes were lower in the EPO-d group than in the con-
trol group. However, the two groups did not differ in
terms of the time to exhaustion at the CS (Tlim). The
[La]INC measured at the end of the incremental exerciseFigure 1 Correlations between hematocrit on one hand and
peak velocity and VO2max on the other.
Table 3 List of significantly up-regulated genes expressed in the tibialis anterior and soleus muscles in EPO-deficient
mice and control mice
Genes Entrez Gene ID Normalized ratio t-test P-value Description
Mcptl 17233 3.25 0.01 mast cell protease-like
Dhrs4 28200 2.55 0.01 dehydrogenase/reductase (SDR family) member 4
Runx1 12394 1.88 0.03 runt related transcription factor 1
3830408D24Rik 100039781 1.87 0.01 RIKEN cDNA 3830408D24 gene
Plcb2 18796 1.87 0.04 phospholipase C, beta 2
1810013L24Rik 69053 1.79 0.05 RIKEN cDNA 1810013L24 gene
Aldh8a1 237320 1.78 0.02 aldehyde dehydrogenase 8 family, member A1
Asp-ARNt_TRND 4555 1.76 0.01 mitochondrially encoded tRNA aspartic acid [ Homo sapiens ]
Ccdc130 67736 1.74 0.02 coiled-coil domain containing 130
Chfr 231600 1.71 0.02 checkpoint with forkhead and ring finger domains
Ints1 68510 1.71 0.02 integrator complex subunit 1
Pip5k2b 108083 1.70 0.02 phosphatidylinositol-5-phosphate 4-kinase, type II, beta
Isg20l2 229504 1.70 0.01 interferon stimulated exonuclease gene 20-like 2
Bace1 23821 1.69 0.04 beta-site APP cleaving enzyme 1
1200015F23Rik 67809 1.68 0.02 RIKEN cDNA 1200015F23 gene
Gmfg 63986 1.67 0.02 glia maturation factor, gamma
BC037032 414066 1.65 0.01 cDNA Sequence BC037032
Zdhhc9 208884 1.65 0.03 zinc finger, DHHC domain containing 9
Metap2 56307 1.62 0.02 methionine aminopeptidase 2
1110008L16Rik 66132 1.61 0.03 RIKEN cDNA 1110008L16 gene
Asn-ARNt_TRNN 4570 1.61 0.00 mitochondrially encoded tRNA asparagine [ Homo sapiens ]
Ube2g1 67128 1.61 0.01 ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans)
4933409D19Rik 71084 1.61 0.05 RIKEN cDNA 4933409D19 gene
Tyr-ARNt_TRNY 4579 1.60 0.03 mitochondrially encoded tRNA tyrosine
Mif 17319 1.60 0.04 macrophage migration inhibitory factor
Olfr1428 258673 1.60 0.03 olfactory receptor 1428
Cygb 114886 1.60 0.03 cytoglobin
Olfr1387 258465 1.59 0.01 olfactory receptor 1387
Adarb1 110532 1.58 0.01 adenosine deaminase, RNA-specific, B1
BC023105 207269 1.58 0.02 cDNA sequence BC023105
Aak1 269774 1.56 0.02 AP2 associated kinase 1
9830134C10Rik 442827 1.56 0.00 RIKEN cDNA 9830134C10 gene
4921530L21Rik 66732 1.55 0.04 RIKEN cDNA 4921530L21 gene
A930014E01Rik 78598 1.52 0.03 RIKEN cDNA A930014E01 gene
Dgkh 380921 1.51 0.04 diacylglycerol kinase, eta
Ccdc72 66167 1.51 0.05 coiled-coil domain containing 72
V1rc1 113858 1.51 0.00 vomeronasal 1 receptor, C1
Zim1 22776 1.51 0.01 zinc finger, imprinted 1
Ace 11421 1.50 0.04 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Xrcc6 14375 1.50 0.01 X-ray repair complementing defective repair in Chinese
hamster cells 6
Dcun1d3 233805 1.50 0.02 DCN1, defective in cullin neddylation 1, domain containing 3
(S. cerevisiae)
Adam28 13522 1.49 0.04 a disintegrin and metallopeptidase domain 28
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Table 3 List of significantly up-regulated genes expressed in the tibialis anterior and soleus muscles in EPO-deficient
mice and control mice (Continued)
Adamts10 224697 1.49 0.03 a disintegrin-like and metallopeptidase (reprolysin type) with
thrombospondin type 1 motif, 10
Bach2 12014 1.46 0.03 BTB and CNC homology 2
Cbl 12402 1.46 0.01 Casitas B-lineage lymphoma
Hist1h2an 319170 1.46 0.02 histone cluster 1, H2an
Eif5a 276770 1.45 0.05 eukaryotic translation initiation factor 5A
Zcchc2 227449 1.45 0.02 zinc finger, CCHC domain containing 2
Stk24 223255 1.45 0.05 serine/threonine kinase 24 (STE20 homolog, yeast)
B4galt3 57370 1.45 0.02 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 3
Tprkb 69786 1.44 0.00 Tp53rk binding protein
Sfpq 71514 1.44 0.05 splicing factor proline/glutamine rich (polypyrimidine tract
binding protein associated)
Foxo1 56458 1.44 0.02 forkhead box O1
4933436I01Rik 66780 1.44 0.03 RIKEN cDNA 4933436I01 gene
9830107B12Rik 328829 1.43 0.01 RIKEN cDNA 9830107B12 gene
Dhx30 72831 1.43 0.02 DEAH (Asp-Glu-Ala-His) box polypeptide 30
Sema3e 20349 1.43 0.01 sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3E
Vps37b 330192 1.42 0.03 vacuolar protein sorting 37B (yeast)
AI662250 106639 1.41 0.05 expressed sequence AI662250
Arhgap26 71302 1.41 0.01 Rho GTPase activating protein 26
4930434E21Rik 381693 1.41 0.04 RIKEN cDNA 4930434E21 gene
1500001A10Rik 68955 1.41 0.02 RIKEN cDNA 1500001A10 gene
Prtg 235472 1.40 0.00 protogenin homolog (Gallus gallus)
Lefty2 320202 1.40 0.02 Left-right determination factor 2
4933431J24Rik 71298 1.40 0.00 RIKEN cDNA 4933431J24 gene
Opn1sw 12057 1.40 0.01 opsin 1 (cone pigments), short-wave-sensitive (color blindness, tritan)
Vcpip1 70675 1.40 0.01 valosin containing protein (p97)/p47 complex interacting protein 1
Defb37 353320 1.40 0.01 defensin beta 37
A p-value <0.05 indicates that the expression ratio differed significantly from 1.
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values measured at the end of steady-state exercise at
the CS were similar (Table 2).
The VO2max and vPeak were correlated with the Htc
in each group separately and when pooled (p < 0.05)
(Figure 1). In the control group, there was a correlation
between the Htc and the CS (r =0.828 , p < 0.05).
Gene expression in skeletal muscles
Thirty-three percent of the microarray probes (especially
those for mitochondrial genes) hybridized with a signifi-
cantly high fluorescence value. All the data from the
present study have been deposited in the Gene Expres-
sion Omnibus (accession number pending). After filter-
ing the normalized expression ratios with a cut-off at
p < 0.05 (i.e. a significant difference from 1), a total of
1583 genes exhibited significant changes of expressionlevels between the EPO-d and the control mice
(Additional file 1: Table S1). Most of the changes were
moderate (0.80 < normalized ratio < 1.4). However, 68
genes were strongly up-regulated genes (normalized
ratio > 1.4) and 115 were strongly down-regulated (nor-
malized ratio <0.80) (Tables 3 and 4).
The changes for 23 strongly up- and down-regulated
genes (according to the microarray analysis) were vali-
dated by RT-qPCR analysis (Table 5). The gene expres-
sion values (Ct) did not depend significantly on the type
of muscle (the tibialis anterior vs. the soleus) but there
was a statistically significant interaction with the EPO-d
treatment factor. There was a significant Pearson correl-
ation of 0.87 (p < 0.01) for the expression values of 19
genes tested by the two methods RT-qPCR and micro-
array analysis, respectively. Despite the differences in
methodologies, gene probes and primers, the regulation
Table 4 List of significantly down-regulated genes expressed in the tibialis anterior and soleus muscles in EPO-d mice
and control mice
Genes Entrez Gene ID Normalized ratio t-test P-value Description
Ckm 12715 0.52 0.00 creatine kinase, muscle
Eno3 13808 0.53 0.01 enolase 3, beta muscle
Serpinb2 18788 0.57 0.04 serine (or cysteine) peptidase inhibitor, clade B, member 2
Apool 68117 0.58 0.02 apolipoprotein O-like
Hspb7 29818 0.58 0.03 heat shock protein family, member 7 (cardiovascular)
Chac1 69065 0.60 0.04 ChaC, cation transport regulator-like 1 (E. coli)
Cln3 12752 0.61 0.01 ceroid lipofuscinosis, neuronal 3, juvenile
(Batten, Spielmeyer-Vogt disease)
Nrap 18175 0.63 0.00 nebulin-related anchoring protein
Zyg11b 414872 0.63 0.00 zyg-ll homolog B (C. elegans)
Zp2 22787 0.65 0.00 zona pellucida glycoprotein 2
Atp1a2 98660 0.66 0.01 ATPase, Na+/K+ transporting, alpha 2 polypeptide
Ctsd 13033 0.66 0.00 cathepsin D
Lrrc42 77809 0.66 0.01 leucine rich repeat containing 42
Ppp3ca 19055 0.67 0.01 protein phosphatase 3, catalytic subunit, alpha isoform
1600014E20Rik 71995 0.67 0.04 endogenous retroviral sequence 3
Kcnb1 16500 0.67 0.02 potassium voltage gated channel, Shab-related
subfamily, member 1
1700052M18Rik 78415 0.68 0.04 RIKEN cDNA 1700052M18 gene
C1qtnf4 67445 0.68 0.03 C1q and tumor necrosis factor related protein 4
Setd3 52690 0.68 0.05 SET domain containing 3
Rtn2 20167 0.69 0.01 reticulon 2 (Z-band associated protein)
1110018H23Rik 68509 0.69 0.01 RIKEN cDNA 1110018H23 gene
Mgat2 217664 0.69 0.03 mannoside acetylglucosaminyltransferase 2
Smpd1 20597 0.70 0.02 sphingomyelin phosphodiesterase 1, acid lysosomal
Tbcc 72726 0.71 0.02 tubulin-specific chaperone c
Zfand5 22682 0.72 0.01 zinc finger, AN1-type domain 5
Tuba8 53857 0.72 0.02 tubulin, alpha 8
Fndc5 384061 0.73 0.02 fibronectin type III domain containing 5
Magea5 17141 0.73 0.04 melanoma antigen, family A, 5
Actg2 11468 0.73 0.03 actin, gamma 2, smooth muscle, enteric
Galnt14 71685 0.74 0.01 UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 14
2610019E17Rik 75614 0.74 0.01 RIKEN cDNA 2610019E17 gene
Scn4b 399548 0.74 0.00 sodium channel, type IV, beta
Olfr1370 258528 0.74 0.03 olfactory receptor 1370
Cbln2 12405 0.74 0.02 cerebellin 2 precursor protein
4933406C10Rik 74076 0.74 0.04 RIKEN cDNA 4933406C10 gene
Zfp618 72701 0.75 0.00 zinc fingerprotein 618
Slc2a4 6517 0.75 0.01 solute carrier family 2 (facilitated glucose transporter),
member 4 [ Homo sapiens ]
Stx3 20908 0.75 0.01 syntaxin 3
Mdh2 4191 0.75 0.03 malate dehydrogenase 2, NAD (mitochondrial)
[ Homo sapiens ]
Chchd6 66098 0.75 0.05 coiled-coil-helix-coiled-coil-helix domain containing 6
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Table 4 List of significantly down-regulated genes expressed in the tibialis anterior and soleus muscles in EPO-d mice
and control mice (Continued)
Gpsn2 106529 0.75 0.00 glycoprotein, synaptic 2
D230014K01Rik 217364 0.76 0.02 RIKEN cDNA D230014K01 gene
Zfp286 192651 0.76 0.04 zinc finger protein 286
Pctk1 18555 0.76 0.03 PCTAIRE-motif protein kinase 1
1700008N11Rik 75442 0.76 0.03 RIKEN cDNA 1700008N11 gene
1700015C15Rik 75532 0.76 0.02 RIKEN cDNA 1700015C15 gene
Uqcrc1 22273 0.76 0.00 ubiquinol-cytochrome c reductase core protein 1
Abi3 66610 0.77 0.02 ABI gene family, member 3
Vat1 26949 0.77 0.00 vesicle amine transport protein 1 homolog (T californica)
Snw1 66354 0.77 0.04 SNW domain containing 1
Eef1a2 13628 0.77 0.01 eukaryotic translation elongation factor 1 alpha 2
Nme5 75533 0.77 0.01 expressed in non-metastatic cells 5
Fxyd1 56188 0.77 0.03 FXYD domain-containing ion transport regulator 1
1700039E22Rik 73322 0.77 0.01 RIKEN cDNA 1700039E22 gene
Herpud1 64209 0.77 0.02 homocysteine-inducible, endoplasmic reticulum
stress-inducible, ubiquitin-like domain member 1
Pms2 18861 0.77 0.04 postmeiotic segregation increased 2 (S. cerevisiae)
Gli3 14634 0.77 0.05 GLI-Kruppel family member GLI3
Eef2 13629 0.78 0.01 eukaryotic translation elongation factor 2
Perld1 320655 0.78 0.03 per1-like domain containing 1
Pbxip1 229534 0.78 0.01 pre-B-cell leukemia transcription factor interacting protein 1
Ncf1 17969 0.78 0.03 neutrophil cytosolic factor 1
Olfr745 258296 0.78 0.03 olfactory receptor 745
Wfikkn2 278507 0.78 0.01 WAP, follistatin/kazal, immunoglobulin, kunitz and netrin
domain containing 2
Syngr2 20973 0.78 0.01 synaptogyrin 2
Eml4 78798 0.78 0.04 echinoderm microtubule associated protein like 4
4930564G21Rik 75321 0.78 0.03 RIKEN cDNA 4930564G21 gene
B230217C12Rik 68127 0.78 0.02 RIKEN cDNA B230217C12 gene
1810054G18Rik 75660 0.78 0.00 lin-37 homolog (C. elegans)
Psmd4 19185 0.78 0.01 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4
Rab14 68365 0.78 0.04 RAB14, member RAS oncogene family
Slc15a4 100561 0.78 0.03 solute carrier family 15, member 4
Rcl1 59028 0.79 0.03 RNA terminal phosphate cyclase-like 1
Ndufa3 66091 0.79 0.01 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
Tpmt 22017 0.79 0.02 thiopurine methyltransferase
Twf2 23999 0.79 0.01 twinfilin, actin-binding protein, homolog 2 (Drosophila)
Rbpjl 19668 0.79 0.01 recombination signal binding protein for immunoglobulin
kappa J region-like
Gngt2 14710 0.79 0.04 guanine nucleotide binding protein (G protein), gamma
transducing activity polypeptide 2
Lmln 239833 0.79 0.03 leishmanolysin-like (metallopeptidase M8 family)
Olfr1433 258680 0.79 0.01 olfactory receptor 1433
2210404E10Rik 72305 0.79 0.02 RIKEN cDNA 2210404E10 gene
Sod1 20655 0.79 0.05 superoxide dismutase 1, soluble
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Table 4 List of significantly down-regulated genes expressed in the tibialis anterior and soleus muscles in EPO-d mice
and control mice (Continued)
2310007L24Rik 75573 0.79 0.02 RIKEN cDNA 2310007L24 gene
Asrgl1 66514 0.79 0.00 asparaginase like 1
Wdr54 75659 0.79 0.02 WD repeat domain 54
Ociad2 433904 0.79 0.01 OCIA domain containing 2
Atg9a 245860 0.79 0.05 autophagy-related 9A (yeast)
Rbm38 56190 0.79 0.01 RNA binding motif protein 38
Psmb5 19173 0.79 0.02 proteasome (prosome, macropain) subunit, beta type 5
Slc30a9 109108 0.79 0.03 solute carrier family 30 (zinc transporter), member 9
Agr2 23795 0.79 0.02 anterior gradient 2 (Xenopus laevis)
Cpne3 70568 0.79 0.01 copine III
Tbc1d1 57915 0.80 0.03 TBC1 domain family, member 1
Cacng6 54378 0.80 0.04 calcium channel, voltage-dependent, gamma subunit 6
5730494M16Rik 66648 0.80 0.01 RIKEN cDNA 5730494M16 gene
Olfr127 258374 0.80 0.03 olfactory receptor 127
4933408N05Rik 71122 0.80 0.03 RIKEN cDNA 4933408N05 gene
4930547E14Rik 75145 0.80 0.01 RIKEN cDNA 4930547E14 gene
Dhrs1 52585 0.80 0.00 dehydrogenase/reductase (SDR family) member 1
Bcat2 12036 0.80 0.01 branched chain aminotransferase 2, mitochondrial
1700012J22Rik 75496 0.80 0.04 RIKEN cDNA 1700012J22 gene
Efcbp2 117148 0.80 0.00 EF hand calcium binding protein 2
Rab23 19335 0.80 0.02 RAB23, member RAS oncogene family
Gpld1 14756 0.80 0.00 glycosylphosphatidylinositol specific phospholipase D1
Tomm40 53333 0.80 0.05 translocase of outer mitochondrial membrane
40 homolog (yeast)
Tln1 21894 0.80 0.01 talin 1
Tsc22d4 78829 0.80 0.01 TSC22 domain family 4
Dnahc1 110084 0.80 0.03 dynein, axonemal, heavy chain 1
1700128I11Rik 73615 0.80 0.03 RIKEN cDNA 1700128I11 gene
Tcf4 21413 0.80 0.01 transcription factor 4
A p-value <0.05 indicates that the expression ratio differed significantly from 1.
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genes. Two genomic markers of hypoxia (hypoxia-indu-
cible factor 1 alpha subunit (Hif1a) and vascular endo-
thelial growth factor alpha (VEGF-alpha)) were
significantly up-regulated in RT-qPCR but not in the
microarray analysis after filtering for the p-value (slight
up-regulation (1 < normalized ratio <1.2); p = 0.21 and
0.22, respectively.
Gene functions and pathways
We used Ingenuity Pathway AnalysisW to classify our list
of modulated genes by cellular function and by canonical
and signaling pathway. Three groups of functions were
detected (Table 6): (i) catabolic pathways, including cell
death, protein degradation and lipid metabolism, (ii)
anabolic pathways, including protein synthesis, cell cycle,growth and proliferation, DNA replication, cellular as-
sembly and molecular transport; (iii) communication,
with cell-to-cell signaling and cell signaling. Cell death,
protein synthesis, cellular growth and proliferation and
lipid metabolism were the main cell functions that were
significant associated with between 9 and 12 modulated
genes (Table 6).
The tissue, organ and cellular context and the asso-
ciated biological activities were further investigated with
a PredictsearchW analysis. Using the PubMed database, it
was found that 31 of the significantly modulated genes
were strongly associated with the following biological ac-
tivities: apoptosis, proteolysis, glycolysis, cellular traffick-
ing and cytoskeleton. In addition, the most frequently
cited disease pathways in relation to the gene set were
muscle atrophy, hypoxia and oxidative stress. The main
Table 5 RT-qPCR results for 23 genes that were up- or down-regulated according to the microarray analysis
Detector Ct Epo-d mice Ct control mice 2-ddCt (fold change) Microarray normalized ratio
Serpinb2 26.13 12.84 9.90E-05 0.57
Nrap 24.00 12.64 3.76E-04 0.63
Chfr 19.55 14.23 2.48E-02 1.71
Plcb2 20.42 16.01 4.66E-02 1.87
Chac1 15.50 11.66 6.93E-02 0.6
Ctsd 16.82 13.12 7.68E-02 0.66
Pip4k2b 15.07 12.43 0.16 1.70
Runx1 19.07 17.73 0.39 1.88
Eno3 13.69 12.71 0.51 0.53
Mcptl 13.48 12.63 0.55 3.25
Atp1a2 12.90 12.62 0.82 0.66
Hspb7 12.67 12.78 1.08 0.58
Socs3 15.95 16.60 1.55 0.88
Ccdc130 12.38 13.31 1.90 1.74
Isg20l2 12.45 13.61 2.22 1.70
Ckm 12.26 13.58 2.47 0.52
Ints1 18.37 19.98 3.03 1.71
Zp2 10.82 12.74 3.76 0.65
Erk1 14.33 24.29 982.97 1.11
Epor 13.83 12.85 0.50 NA
Cish2 12.89 12.90 1.00 NA
Vegf 13.04 13.89 1.79 NA
Hif1a 14.08 19.84 53.82 NA
The averaged Ct values of the triplicate analysis are quoted for EPO-deficient and control mice. The Ct values were normalized against Cish2 expression because
the latter was not affected by the EPO deficiency. The relative expression of each gene in EPO-deficient mice was calculated by comparison with the
corresponding gene expression in control mice. There was a statistically significant correlation (Pearson coefficient: 0.87; p < 0.01) between the expression values
for 19 genes according to the RT-qPCR assays and the expression values according to the microarray analysis.
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mining are described in Figures 2, 3, 4 and 5.
The forkhead box O1 (Foxo1) gene was significantly
over-expressed and may activate muscle proteolysis in
conjunction with three other up-regulated genes
involved in the muscle proteasome (Ube2g1) and E3
Ubiquitin ligase (Chfr and Cbl) (Figure 2). Chronic pro-
teolysis of myofibrils may be responsible for muscle at-
rophy. Glucose import into muscle cells by the glucose
transporter type 4, insulin-responsive (Slc2a4/Glut4),
was down-regulated and probably contributed to a de-
crease in ATP production. In addition, several genes
coding for key enzymes in glycolysis (Pfkm, Eno3 and
Gapdh), mitochondrial oxidative phosphorylation
(NADH dehydrogenase unit Ndufa3) and the muscle
creatine kinase (Ckm) were down-regulated. The two
genomic markers of muscle hypoxia (Hif1a and Vegf )
were up-regulated. Low mitochondrial activity seemed
to be related to hypoxia signaling with two up-regulated
downstream genes: cytoglobin (Cygb) and macrophage
migration inhibitory factor (Mif ). The up-regulation ofFoxo1 gene could be interpreted as a signal of anti-
oxidant response by the muscle cells, with up-regulation
of glycoprotein-4-beta-galactosyltransferase 2 (B4galt)
and eukaryotic translation initiation factor 4 gamma
(Elf4g2) and down-regulation of ceroid lipofuscinosis
neuronal 3 (Cln3).
Seven genes coding for cytoskeleton components were
moderately up-regulated (1 < x < 1.4) and all the other
genes were moderately or significantly down-regulated
(Figure 4). These down-regulations may affect the syn-
thesis of the cytoskeleton proteins: actin, tubulin, tropo-
nin and myosin. Decreased expression of the genes
coding for cytoskeleton components and ATP produc-
tion by glycolysis may be related to the decrease in intra-
cellular trafficking (Figure 5). Mitochondrial protein
import was probably decreased by the concomitant
down-regulation of five genes: Tomm40, Ckm, Mdh2,
Rtn2 and Uqcr1. These changes may also have contribu-
ted to the decrease in mitochondrial oxidative phosphoryl-
ation activity. The insulin-responsive vesicles transporting
glucose into the cells (Sclc2a4/Glut4; Syngr2) and





Cell Death 12 3.47E-05 - 4.53E-02 METAP2 (includes EG:10988), BACE1, ACE, CHFR, MIF,
ATP1A2, SERPINB2, CLN3, RUNX1, GMFG, XRCC6, CTSD
Protein Synthesis 11 1.77E-05 - 4.53E-02 TRNY, METAP2 (includes EG:10988), TRNN, ACE, BACE1,
CHFR, MIF, CLN3, TRND, UBE2G1, CTSD
Cellular Growth and Proliferation 9 1.06E-03 - 4.53E-02 PIP4K2B, METAP2 (includes EG:10988), CHFR, MIF, CLN3,
SERPINB2, RUNX1, CTSD, XRCC6
Lipid Metabolism 9 2.41E-03 - 4.53E-02 PIP4K2B, DHRS4, ALDH8A1, CYGB, ACE, MIF, CLN3, RUNX1, PLCB2
Molecular Transport 8 5.13E-03 - 4.53E-02 ALDH8A1, ACE, MIF, CLN3, ATP1A2, RUNX1, PLCB2, CKM
Cellular Assembly and Organization 7 2.57E-03 - 4.53E-02 METAP2 (includes EG:10988), ACE, BACE1, CLN3, CKM, XRCC6, CTSD
Protein Degradation 6 1.31E-04 - 5.4E-03 ACE, BACE1, CHFR, CLN3, UBE2G1, CTSD
Cardiovascular System Development
and Function
5 1.43E-03 - 4.56E-02 METAP2 (includes EG:10988), ACE, MIF, ATP1A2, RUNX1
DNA Replication, Recombination,
and Repair
5 7.69E-03 - 4.78E-02 METAP2 (includes EG:10988), CHFR, MIF, ATP1A2, XRCC6
Hematological System Development
and Function
4 1.06E-03 - 4.04E-02 ACE, MIF, SERPINB2, RUNX1
Cell-To-Cell Signaling and Interaction 4 1.3E-03 - 4.53E-02 METAP2 (includes EG:10988), ACE, MIF, ZP2
Cell Cycle 4 2.57E-03 - 4.78E-02 METAP2 (includes EG:10988), CHFR, MIF, RUNX1
Cell Signaling 2 1.28E-02 - 2.29E-02 PLCB2, CKM
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and Ctsd) were significantly down-regulated. Protein deg-
radation in the proteasome was stimulated by the up-
regulated ubiquitin-conjugating enzyme (Ube2g1) and
the down-regulated zinc finger protein (Zfand5/Znf216).
Down-regulation of the cation transport regulator-like
protein 1 (Chac1) may contribute to the inhibition of
apoptosis. The cell survival factor serine (or cysteine
or plasminogen) peptidase inhibitor (Serpinb2/Pai-2) was
strongly down-regulated and would not have provided its
usual cell protection activity.
Discussion
Most of the studies on muscle exercise or doping are
based on the use of acute or chronic EPO injection to
stimulate endurance capacity. In the present study, the
EPO-d model was used to study the effects of EPO loss-
of-function on the muscles of exercising mice. To date,
the study of adult EPO-d animals has been limited by
the fact that EPO gene knock-out (KO) is embryonic le-
thal [35,36]. Protein functional knock-out by immuno-
neutralization of circulating EPO is a novel way of
inducing EPO deficiency in live, active mice [27]. Thus,
the effects of the EPO deficiency were evaluated through
an integrative biology approach in order to reveal poten-
tial consequences at the physiologic and genomic levels.
The EPO-d mice had an Htc of about 20%, i.e. two-fold
lower than in control mice and much lower than the
value of 58% for maximal exercise performance in wild-type mice [37]. However, this low Htc did not prevent
the performance of valid exercise tests. Another type of
murine EPO-d model is the EPO-Tagh transgenic mouse,
which displayed about the same, low Htc (19.3%) in nor-
moxia as in our model [38]. After two weeks of rest, the
researchers did not observe an elevation in Hif1a or
muscle atrophy - suggesting that a lack of EPO does not
cause structural damage to muscles. However, the stud-
ied animals did not perform exercise. In fact, the
observed activation of the EPO-R by acute exercise sug-
gests that physiological levels of EPO do have a role in
exercising muscle tissue [12]. Indeed, the combination of
exercise and chronic EPO deficiency in the present study
resulted in hypoxia with Hif1a accumulation and muscle
atrophy.
In the present study, reductions of between 25% and
30% in vPeak, VO2max, and CS attested to the subnormal
exercise performance in EPO-d mice. However, the time
to exhaustion was not different between groups. This is
not consistent with the 50% decrease (vs. controls) in
the time to exhaustion in a swimming test observed in a
murine CKF model with a low Htc (28% lower than in
controls). However, the intensity of the swimming exer-
cise was not quantified and the absolute intensity was
probably similar in the two groups. In the present study,
performance was first assessed in terms of vPeak and
VO2max. Next, the intensity chosen for the exhaustive
exercise (at CS) was individually related to performance
(at around 80% of vPeak); thus, all mice were exercising
Figure 2 Main pathway disorders leading to muscle proteolysis, atrophy, hypoxia and anti-oxidant response. Legends of the figures 2-5
are indicated under this figure.
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that the time to exhaustion was similar in the two
groups and confirmed the relevance of CS in the run-
ning mouse model [30]. Furthermore, VO2max wascorrelated with the Htc as previously observed by Schu-
ler (2010). This relation is valid in each group and in the
whole study population. These results validate this EPO-
d mouse model in physiological terms. However, in the
Figure 3 Impairment in ATP production. Impaired ATP production, with down-regulation of genes involved in glycolysis,
mitochondrial oxidative phosphorylation and the phosphocreatine kinase pathway. Other than some moderately up- or down-regulated
subunits of NADH dehydrogenase, most of the genes were down-regulated. Legends of this figure are provided in Figure 2.
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This question is controversial; in general, total
hemoglobin is correlated with VO2max rather than Htc.
Indeed, elevated hemoglobin is correlated with an ele-
vated VO2max in humans [39] and there is an optimal
Htc (57%-58%) for a maximal performance in EPO-
treated mice [37]. Above this level, performance levels
decrease and excessive erythrocytosis leads to multiple
organ degeneration, including damage to heart and skel-
etal muscles [40,41]. The impact of hemoglobin concen-
tration on VO2max becomes greater under non-
physiological conditions (such as blood loss or doping).
Indeed, data from anti-doping studies generally show a
similar relationship between the hemoglobin concentra-
tion and VO2max, as observed after blood loss [39]. How-
ever, in contrast with data from humans, the control
mice in the present study showed a significant correl-
ation between Htc vs. VO2max. (i.e. in the physiological
range).
This set of physiological results emphasized the poor
endurance capacity in EPO-d mice, which may be
related to their impaired aerobic capacity relative to con-
trol mice. They exhibited a lower VO2max and higher
blood [La]INC which are physiological signs of hypoxia.This was confirmed at the genomic level by strong up-
regulation of Hif1a, which acts as the master regulator
for the expression of genes involved in the hypoxia re-
sponse in most mammalian cells [42,43]. There were
some indirect signs of muscle hypoxia, with the up-
regulation of Vegf, Cygb and Mif. In addition, some
NADH sub-units involved in mitochondrial oxidative
phosphorylation and other genes coding for mitochon-
drial proteins (Ckm, Mdh2, Tomm40, Rtn2, Uqcrc1)
were down-regulated. Chronic muscle hypoxia could be
directly related to the animals’ low Htc and the drop of
oxygen tension in the muscle fibers and mitochondria.
This hypoxia was associated with cell oxidative stress, as
indicated by the up-regulation of the Foxo1 marker. On
the mitochondrial level, it has been reported that about
2% of the oxygen used by the respiratory chain is incom-
pletely reduced and produces superoxide radicals [44].
The overproduction of reactive oxygen species (ROS) in
hypoxia is a surprising finding but has been previously
described in hypoxic cardiomyocytes [45] and in muscles
with glycogenosis and mitochondrial dysfunction [46]. In
the present study, we found that several genes coding
for NADH subunits were down-regulated, resulting in
uncoupling with the Krebs cycle. Thus, the respiratory
Figure 4 The gene regulation of cytoskeleton components. None of the genes were significantly up-regulated (x > 1.4) but seven were
moderately up-regulated ( 1 > x > 1.4). All other genes in this category were moderately or severely down-regulated. Legends of this figure are
provided in Figure 2.
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duction and would provide electrons for ROS gener-
ation. If O2 is not entirely reduced to water by complex
IV, ROS generation seems to contribute to the O2 signal-
ing pathway [47]. The ROS-like superoxide anion radical
O2
- , hydrogen peroxide and the hydroxyl radical .OH are
all able to damage proteins, DNA and membranes. How-
ever, the generation of .OH from hydrogen peroxide by
an iron-dependent Fenton reaction within or close to
the nucleus could trigger the expression of redox-
sensitive transcription factors such as Hif1a. Thus, ROS
generation could be the primary messenger responsible
for Hif1 transcription factor regulation, which may ex-
plain the relationship between oxidative stress and
hypoxia.
The present transcriptome data mining analysis
showed that the EPO deficiency induced expression
changes in genes related to muscle hypoxia and prote-
olysis. In addition, 12 significantly modulated genes were
involved in cell death and apoptosis (Table 6). Thus, one
can assume that physiological concentrations of circulat-
ing EPO have a muscle-protecting effect. It has been
reported that after acute exercise, EPO-Rs are up-regulated in satellite cells and muscle fibers - suggesting
a muscle-specific EPO signaling pathway [12]. The
muscle-protecting effect of EPO could be related to
anti-apoptotic activity, as has been demonstrated in a
model of cadiomyocyte ischemia [48]. In fact, EPO acti-
vates (through the EPO-R) the PI3 kinase /Akt signaling
pathway and thus increases both eNOS expression and
phosphorylation. Production of NO by eNOS inhibits
cardiomyocyte apoptosis. The NO has both anti-
apoptotic and pro-apoptotic activities by modulating
multiple sites in the death signaling pathway and the
mitochondrial apoptosis pathway [49]. However, most of
the anti-apoptotic activity seems to occur via an increase
in Bcl-2 expression and prevention of cytochrome c re-
lease from the mitochondria. Other pathways may have
a muscle-protective effect, such as L-type calcium chan-
nel inhibition and the up-regulation of protective pro-
teins (such as heme-oxygenase-1, heat shock proteins
Hsp70 and metallothionein).
In the present study, some results were consistent with
a potential role of EPO in the anti-apoptotic pathway in
exercising muscle. We found that EPO-R, nitric oxide
synthase 2 inducible (Nos2) and Akt1 were down-
Figure 5 Down-regulation of many genes involved in intracellular trafficking. Legends of this figure are provided in Figure 2.
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muscle protein synthesis and hypertrophy [50]. In con-
trast, EPO injections do not affect EPO-R signaling in
muscles under resting conditions - suggesting an indir-
ect effect of EPO related to an increase in oxidative cap-
acity [51]. We did not detect Hsp70 modulation but two
Hsp90 genes (Hsp90aa1, Hsp90b1) were up-regulated.
The heat shock protein 90 family is known to stabilize
and accumulate Hif1a under hypoxic conditions, which
is consistent with our observation in an RT-qPCR that
Hif1a was highly up-regulated [52]. It has been reported
that EPO may also exert an anti-oxidant effect in the
blood vessels by up-regulating superoxide dismutase
(Sod1) [53]. These previous results may be related to our
finding of muscle oxidative stress in EPO-d mice, with a
combination of down-regulation of Sod1 and up-
regulation of Foxo1 as a response to oxidative stress.
Low muscle oxidative stress stimulates muscle adapta-
tion and performance levels but high oxidative stress
decreases muscle force production by inhibiting the
sarcoplasmic calcium ATPase (Serca) [54], which mayexplain the poor exercise performance of the EPO-d
mice in the present study. In addition, it has been shown
that oxidative stress contributes to the increase in
muscle atrophy by accelerating muscle protein degrad-
ation by the calpains and caspase-3 [55]. However, this
observation was made in isolated muscle fibers in vitro
and one can legitimately suppose that exercise activity
may increase this phenomenon, since we observed major
proteolysis activity in the present transcriptome analysis.
Taken as a whole, our present results and literature data
prompted us to suggest a putative signaling pathway that
may explain EPO's direct and indirect protective effects
on skeletal muscle (Figure 6). Moreover, the transgenic
rescued EPO-R-null mutant mice would be an interest-
ing tool for elucidating the relative contributions of
EPO's various non-hematopoietic effects [56].
Conclusion
From a physiological point of view, our study validated
the EPO-d mouse model by demonstrating worse exer-
cise performance than in control mice with a normal
Figure 6 Overview of the direct and indirect effects of EPO loss-of-function on muscle. On the basis of the present study's results, our
model seeks to explain the impact of a lack of functional EPO on muscle tissue in the EPO-d mouse.
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by the lower Htc, chronic hypoxia, muscle oxidative
stress and the severe muscular proteolysis revealed by
the transcriptome analysis. Our results suggest that
physiological levels of EPO cytokine exert both direct
and indirect protective effects on muscle during exercise.
However, the signaling pathway involved in these pro-
tective effects remains to be described in detail.
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ratio differed significantly from 1.
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